Funding for innovative projects on new treatment modalities such as targeted therapies and immune therapies.

The 2021 LCRF-AstraZeneca grant program aims to fund innovative projects to:

Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations

Develop more effective approaches to address disease progression in patients treated with durvalumab

Discover novel biomarkers for predicting response to osimertinib or durvalumab and to identify patients who are at higher risk of recurrence (translational research preferred)

Identify predictive biomarkers, understand the underlying biology and develop novel interventions for immune mediated adverse events, such as pneumonitis, in patients receiving durvalumab. Proposals which specifically focus on either osimertinib or durvalumab will be strongly favored.

Duration

2 years

Funding

$150,000 for a period of two years (disbursed at $75,000 per year)

Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years' experience since their initial faculty appointment.

Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status.

Senior investigators with more than ten years' experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process.

However, exceptions will be made for investigators with more than ten years' experience in other disease areas or topics. Ineligible investigators with these or other special circumstances may request review by contacting the LCRF grants office.

All applications must be submitted through LCRF's online grants management system: https://lcrf.org/grantinterface

Previews of the LOI and full application may be accessed at http://lcrf.org/application_preview

Applications must be submitted through a two-stage process:

A letter of intent (LOI): deadline April 30th

A full proposal(under invitation); deadline August 27^th

In case of interest, contact wit FSJD Research Dpt.